Squarepoint
DFTX

Squarepoint’s Definium Therapeutics DFTX Stock Holding History

Squarepoint’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.37M Buy
125,522
+80,120
+176% +$1.36M ﹤0.01% 2056
2025
Q4 		$608K Buy
+45,402
New +$562K ﹤0.01% 3052
2025
Q3 		– Sell
-19,684
Closed -$128K – 4743
2025
Q2 		$128K Sell
19,684
-3,787
-16% -$24.9K ﹤0.01% 4104
2025
Q1 		$137K Sell
23,471
-18,497
-44% -$132K ﹤0.01% 4131
2024
Q4 		$292K Sell
41,968
-38,153
-48% -$263K ﹤0.01% 4165
2024
Q3 		$456K Buy
+80,121
New +$557K ﹤0.01% 3170
2024
Q2 		– Sell
-57,650
Closed -$504K – 4435
2024
Q1 		$542K Buy
+57,650
New +$329K ﹤0.01% 2989
2022
Q3 		– Sell
-2,779
Closed -$27K – 3254
2022
Q2 		$27K Sell
2,779
-2,430
-47% -$30.7K ﹤0.01% 2756
2022
Q1 		$87K Buy
5,209
+2,889
+125% +$50.1K ﹤0.01% 2621
2021
Q4 		$48K Buy
2,320
+1,559
+205% +$49.8K ﹤0.01% 3027
2021
Q3 		$27K Buy
+761
New +$32.9K ﹤0.01% 2811

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Squarepoint's DFTX Position: Q1 2026 in Review

Squarepoint increased its Definium Therapeutics (DFTX) stake by 176% in Q1 2026, buying an estimated $1.36M and bringing the position to 125,522 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2056.

Squarepoint first reported a position in DFTX in Q3 2021 and has held it in 11 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Squarepoint held 125,522 shares of Definium Therapeutics worth $2.37M as of Q1 2026.
  • Squarepoint bought 80,120 Definium Therapeutics shares in Q1 2026, an estimated $1.36M.
  • Definium Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2056 holding.
  • Squarepoint first reported a position in Definium Therapeutics in Q3 2021 and has held it in 11 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.